Half-year report · HY
2796.TEDINET S100XF31
Period2025-06-01 → 2025-11-30
Filed2026-01-09
StandardJapan GAAP
ConsolidatedYes
Data checks14 of 14 passed
Key figures · 45
| Metric | Value | Period | Scope | Source row |
|---|---|---|---|---|
| Revenue | ¥33.6bn | 2025-06-01 → 2025-11-30 | Cons. | Net sales |
| Revenue | ¥63.5bn | 2024-06-01 → 2025-05-31 | Cons. | Net sales (5-year summary) |
| Revenue | ¥30.5bn | 2024-06-01 → 2024-11-30 | Cons. | Net sales |
| Operating income | ¥399m | 2025-06-01 → 2025-11-30 | Cons. | Operating income |
| Operating income | ¥100m | 2024-06-01 → 2024-11-30 | Cons. | Operating income |
| Ordinary income | ¥328m | 2025-06-01 → 2025-11-30 | Cons. | Ordinary income |
| Ordinary income | ¥136m | 2024-06-01 → 2025-05-31 | Cons. | Ordinary income loss (5-year summary) |
| Ordinary income | ¥29m | 2024-06-01 → 2024-11-30 | Cons. | Ordinary income |
| Profit before tax | ¥368m | 2025-06-01 → 2025-11-30 | Cons. | Income before income taxes |
| Profit before tax | ¥34m | 2024-06-01 → 2024-11-30 | Cons. | Income before income taxes |
| Net income (owners) | ¥111m | 2025-06-01 → 2025-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income (owners) | −¥367m | 2024-06-01 → 2025-05-31 | Cons. | Profit loss attributable to owners of parent (5-year summary) |
| Net income (owners) | −¥113m | 2024-06-01 → 2024-11-30 | Cons. | Profit loss attributable to owners of parent |
| Net income | ¥106m | 2025-06-01 → 2025-11-30 | Cons. | Profit loss |
| Net income | −¥121m | 2024-06-01 → 2024-11-30 | Cons. | Profit loss |
| Total assets | ¥30.0bn | at 2025-11-30 | Cons. | Assets |
| Total assets | ¥31.9bn | at 2025-05-31 | Cons. | Assets |
| Total assets | ¥30.5bn | at 2024-11-30 | Cons. | Total assets (5-year summary) |
| Total liabilities | ¥23.1bn | at 2025-11-30 | Cons. | Liabilities |
| Total liabilities | ¥25.0bn | at 2025-05-31 | Cons. | Liabilities |
| Net assets / equity | ¥6.8bn | at 2025-11-30 | Cons. | Net assets |
| Net assets / equity | ¥6.9bn | at 2025-05-31 | Cons. | Net assets |
| Net assets / equity | ¥7.2bn | at 2024-11-30 | Cons. | Net assets (5-year summary) |
| Cash and deposits | ¥2.6bn | at 2025-11-30 | Cons. | Cash and deposits |
| Cash and deposits | ¥4.9bn | at 2025-05-31 | Cons. | Cash and deposits |
| Cash & equivalents | ¥2.6bn | at 2025-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥4.9bn | at 2025-05-31 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.5bn | at 2024-11-30 | Cons. | Cash and cash equivalents |
| Cash & equivalents | ¥7.1bn | at 2024-05-31v | Cons. | Cash and cash equivalents |
| Operating cash flow | −¥220m | 2025-06-01 → 2025-11-30 | Cons. | Net cash provided by used in operating activities |
| Operating cash flow | ¥1.3bn | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in operating activities (5-year summary) |
| Operating cash flow | −¥200m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in operating activities |
| Investing cash flow | −¥449m | 2025-06-01 → 2025-11-30 | Cons. | Net cash provided by used in investment activities |
| Investing cash flow | −¥4.5bn | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in investing activities (5-year summary) |
| Investing cash flow | −¥537m | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in investment activities |
| Financing cash flow | −¥1.7bn | 2025-06-01 → 2025-11-30 | Cons. | Net cash provided by used in financing activities |
| Financing cash flow | ¥939m | 2024-06-01 → 2025-05-31 | Cons. | Net cash provided by used in financing activities (5-year summary) |
| Financing cash flow | ¥1.1bn | 2024-06-01 → 2024-11-30 | Cons. | Net cash provided by used in financing activities |
| EPS (basic) | ¥9.75 | 2025-06-01 → 2025-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-32.48 | 2024-06-01 → 2025-05-31 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (basic) | ¥-10.09 | 2024-06-01 → 2024-11-30 | Cons. | Basic earnings loss per share (5-year summary) |
| EPS (diluted) | ¥9.37 | 2025-06-01 → 2025-11-30 | Cons. | Diluted earnings per share (5-year summary) |
| Equity ratio | 22.1% | at 2025-11-30 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 20.9% | at 2025-05-31 | Cons. | Equity to asset ratio (5-year summary) |
| Equity ratio | 22.6% | at 2024-11-30 | Cons. | Equity to asset ratio (5-year summary) |
Periods use the dates stated in the filing. d = earlier-year period dated by calendar; v = that date confirmed by the company's own earlier filing.
Segments · 44
| Segment | Item | Period | Value |
|---|---|---|---|
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2025-06-01 → 2025-11-30 | ¥459m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2025-06-01 → 2025-11-30 | ¥459m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2025-06-01 → 2025-11-30 | −¥92m |
| Reconciling Itemsreconciling | segment profit | 2025-06-01 → 2025-11-30 | −¥169m |
| Cosmetic Drug And Convenience Storereportable segment | revenue | 2025-06-01 → 2025-11-30 | ¥4.1bn |
| Cosmetic Drug And Convenience Storereportable segment | revenue external | 2025-06-01 → 2025-11-30 | ¥4.1bn |
| Cosmetic Drug And Convenience Storereportable segment | segment profit | 2025-06-01 → 2025-11-30 | −¥21m |
| Custody Of Medical Documentsreportable segment | revenue | 2025-06-01 → 2025-11-30 | ¥322m |
| Custody Of Medical Documentsreportable segment | revenue external | 2025-06-01 → 2025-11-30 | ¥322m |
| Custody Of Medical Documentsreportable segment | segment profit | 2025-06-01 → 2025-11-30 | ¥43m |
| Dispensing Pharmacyreportable segment | revenue | 2025-06-01 → 2025-11-30 | ¥28.5bn |
| Dispensing Pharmacyreportable segment | revenue external | 2025-06-01 → 2025-11-30 | ¥28.5bn |
| Dispensing Pharmacyreportable segment | segment profit | 2025-06-01 → 2025-11-30 | ¥589m |
| Medical Mallreportable segment | revenue | 2025-06-01 → 2025-11-30 | ¥257m |
| Medical Mallreportable segment | revenue external | 2025-06-01 → 2025-11-30 | ¥257m |
| Medical Mallreportable segment | segment profit | 2025-06-01 → 2025-11-30 | ¥48m |
| —segment total | revenue | 2025-06-01 → 2025-11-30 | ¥33.1bn |
| —segment total | revenue external | 2025-06-01 → 2025-11-30 | ¥33.1bn |
| —segment total | segment profit | 2025-06-01 → 2025-11-30 | ¥660m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2025-06-01 → 2025-11-30 | ¥33.6bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2025-06-01 → 2025-11-30 | ¥33.6bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2025-06-01 → 2025-11-30 | ¥568m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue | 2024-06-01 → 2024-11-30 | ¥544m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | revenue external | 2024-06-01 → 2024-11-30 | ¥544m |
| Operating Segments Not Included In Reportable Segments And Other Revenue Generating Business Activitiesother segments | segment profit | 2024-06-01 → 2024-11-30 | −¥6m |
| Reconciling Itemsreconciling | segment profit | 2024-06-01 → 2024-11-30 | −¥175m |
| Cosmetic Drug And Convenience Storereportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥4.5bn |
| Cosmetic Drug And Convenience Storereportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥4.5bn |
| Cosmetic Drug And Convenience Storereportable segment | segment profit | 2024-06-01 → 2024-11-30 | −¥1m |
| Custody Of Medical Documentsreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥311m |
| Custody Of Medical Documentsreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥311m |
| Custody Of Medical Documentsreportable segment | segment profit | 2024-06-01 → 2024-11-30 | ¥22m |
| Dispensing Pharmacyreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥24.9bn |
| Dispensing Pharmacyreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥24.9bn |
| Dispensing Pharmacyreportable segment | segment profit | 2024-06-01 → 2024-11-30 | ¥202m |
| Medical Mallreportable segment | revenue | 2024-06-01 → 2024-11-30 | ¥256m |
| Medical Mallreportable segment | revenue external | 2024-06-01 → 2024-11-30 | ¥256m |
| Medical Mallreportable segment | segment profit | 2024-06-01 → 2024-11-30 | ¥58m |
| —segment total | revenue | 2024-06-01 → 2024-11-30 | ¥30.0bn |
| —segment total | revenue external | 2024-06-01 → 2024-11-30 | ¥30.0bn |
| —segment total | segment profit | 2024-06-01 → 2024-11-30 | ¥282m |
| Total Of Reportable Segments And Otherssegment total | revenue | 2024-06-01 → 2024-11-30 | ¥30.5bn |
| Total Of Reportable Segments And Otherssegment total | revenue external | 2024-06-01 → 2024-11-30 | ¥30.5bn |
| Total Of Reportable Segments And Otherssegment total | segment profit | 2024-06-01 → 2024-11-30 | ¥276m |
Segment names come from EDINET member IDs; not yet mapped to a common taxonomy.
All source rows · 557
| Item | Context | Value | Unit |
|---|---|---|---|
| Interest and dividends income received ope cf inv cf | Prior1InterimDuration | 7000000 | JPY |
| Interest and dividends income received ope cf inv cf | InterimDuration | 6000000 | JPY |
| Interest expenses paid ope cf fin cf | Prior1InterimDuration | -76000000 | JPY |
| Interest expenses paid ope cf fin cf | InterimDuration | -123000000 | JPY |
| Income taxes paid refund ope cf | Prior1InterimDuration | -149000000 | JPY |
| Income taxes paid refund ope cf | InterimDuration | -126000000 | JPY |
| Proceeds from subsidy ope cf | Prior1InterimDuration | 24000000 | JPY |
| Proceeds from subsidy ope cf | InterimDuration | 22000000 | JPY |
| Amount of tax payment of consumption tax of prior years ope cf | Prior1InterimDuration | -51000000 | JPY |
| Amount of tax payment of consumption tax of prior years ope cf | InterimDuration | -19000000 | JPY |
| Net cash provided by used in operating activities | Prior1InterimDuration | -200000000 | JPY |
| Net cash provided by used in operating activities | InterimDuration | -220000000 | JPY |
| Proceeds from sales of short term investment securities inv cf | Prior1InterimDuration | 19000000 | JPY |
| Proceeds from sales of short term investment securities inv cf | InterimDuration | － | JPY |
| Purchase of property plant and equipment inv cf | Prior1InterimDuration | -339000000 | JPY |
| Purchase of property plant and equipment inv cf | InterimDuration | -382000000 | JPY |
| Proceeds from sales of property plant and equipment inv cf | Prior1InterimDuration | 3000000 | JPY |
| Proceeds from sales of property plant and equipment inv cf | InterimDuration | 15000000 | JPY |
| Purchase of intangible assets inv cf | Prior1InterimDuration | -26000000 | JPY |
| Purchase of intangible assets inv cf | InterimDuration | -8000000 | JPY |
| Purchase of stocks of subsidiaries and affiliates inv cf | Prior1InterimDuration | -281000000 | JPY |
| Purchase of stocks of subsidiaries and affiliates inv cf | InterimDuration | － | JPY |
| Purchase of long term prepaid expenses inv cf | Prior1InterimDuration | -7000000 | JPY |
| Purchase of long term prepaid expenses inv cf | InterimDuration | -4000000 | JPY |
| Payments for guarantee deposits inv cf | Prior1InterimDuration | -10000000 | JPY |
| Payments for guarantee deposits inv cf | InterimDuration | -26000000 | JPY |
| Proceeds from collection of guarantee deposits inv cf | Prior1InterimDuration | 27000000 | JPY |
| Proceeds from collection of guarantee deposits inv cf | InterimDuration | 28000000 | JPY |
| Payments of loans receivable inv cf | Prior1InterimDuration | -1000000 | JPY |
| Payments of loans receivable inv cf | InterimDuration | -3000000 | JPY |
| Collection of loans receivable inv cf | Prior1InterimDuration | 0 | JPY |
| Collection of loans receivable inv cf | InterimDuration | 0 | JPY |
| Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | Prior1InterimDuration | -30000000 | JPY |
| Purchase of investments in subsidiaries resulting in change in scope of consolidation inv cf | InterimDuration | － | JPY |
| Proceeds from transfer of business inv cf | Prior1InterimDuration | － | JPY |
| Proceeds from transfer of business inv cf | InterimDuration | 9000000 | JPY |
| Payments for transfer of business2 inv cf | Prior1InterimDuration | － | JPY |
| Payments for transfer of business2 inv cf | InterimDuration | -115000000 | JPY |
| Proceeds from acquisition of businesses inv cf | Prior1InterimDuration | － | JPY |
| Proceeds from acquisition of businesses inv cf | InterimDuration | 18000000 | JPY |
| Other net inv cf | Prior1InterimDuration | 108000000 | JPY |
| Other net inv cf | InterimDuration | 19000000 | JPY |
| Net cash provided by used in investment activities | Prior1InterimDuration | -537000000 | JPY |
| Net cash provided by used in investment activities | InterimDuration | -449000000 | JPY |
| Proceeds from long term loans payable fin cf | Prior1InterimDuration | 4000000000 | JPY |
| Proceeds from long term loans payable fin cf | InterimDuration | － | JPY |
| Repayment of long term loans payable fin cf | Prior1InterimDuration | -2532000000 | JPY |
| Repayment of long term loans payable fin cf | InterimDuration | -1320000000 | JPY |
| Repayments of lease obligations fin cf | Prior1InterimDuration | -104000000 | JPY |
| Repayments of lease obligations fin cf | InterimDuration | -90000000 | JPY |
Every row of the EDINET CSV. Item names are the XBRL element names; filed text is kept in its original Japanese. Filed text is available on Plus and Pro.
Data checks · 14 of 14 passed
| balance sheet identity | pass rounding |
| balance sheet identity | pass |
| dei present | pass |
| period resolution | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net assets | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · net income attributable to parent | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · operating cash flow | pass |
| statement vs summary · revenue | pass |
| statement vs summary · revenue | pass |
| statement vs summary · total assets | pass |
| statement vs summary · total assets | pass |